All In Biotech

Drug Trial Radar · NCT04495179

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Aug 4, 2020

Primary completion

Nov 1, 2021

Study completion Aug 8, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 150 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Progressive Metastatic Castrate-Resistant Prostate Cancer

Interventions

  • AZD4635Drug

    Subjects will receive AZD4635 orally daily

  • DurvalumabDrug

    Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.

  • CabazitaxelDrug

    Subjects will receive intravenous cabazitaxel every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)Time frame: From first dose to first documented progression or death from any cause (whichever comes first) (approximately 1 year)

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Sacramento, California

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    St Louis, Missouri

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Brasschaat, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Bordeaux, France

  • Research Site

    Villejuif, France

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Hospitalet deLlobregat, Spain

  • Research Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.